10x Genomics (NASDAQ:TXG) Issues Earnings Results

10x Genomics (NASDAQ:TXG) posted its quarterly earnings data on Thursday. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.05, Zacks reports. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. 10x Genomics updated its Q4 2025 guidance to EPS.

10x Genomics Trading Down 3.6%

TXG stock traded down $0.49 during trading on Thursday, reaching $13.00. 3,407,211 shares of the stock were exchanged, compared to its average volume of 3,203,421. The firm has a market capitalization of $1.62 billion, a price-to-earnings ratio of -18.57 and a beta of 2.13. The business has a 50 day moving average price of $12.81 and a 200-day moving average price of $11.68. 10x Genomics has a 1 year low of $6.78 and a 1 year high of $17.25.

Analyst Ratings Changes

TXG has been the topic of a number of research reports. Canaccord Genuity Group set a $16.00 price target on shares of 10x Genomics in a research note on Monday, August 11th. Deutsche Bank Aktiengesellschaft set a $14.00 price target on 10x Genomics and gave the stock a “hold” rating in a research note on Friday, August 8th. Morgan Stanley reduced their price objective on 10x Genomics from $18.00 to $17.00 and set an “overweight” rating for the company in a research note on Tuesday, August 12th. Piper Sandler initiated coverage on shares of 10x Genomics in a research note on Thursday, September 11th. They set a “neutral” rating and a $15.00 target price on the stock. Finally, Wall Street Zen raised shares of 10x Genomics from a “hold” rating to a “buy” rating in a report on Friday, October 3rd. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $13.65.

Insider Activity

In other news, CEO Serge Saxonov sold 9,348 shares of the company’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $128,908.92. Following the transaction, the chief executive officer owned 945,892 shares of the company’s stock, valued at $13,043,850.68. This represents a 0.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Adam Taich sold 22,315 shares of the firm’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $307,723.85. Following the sale, the chief financial officer directly owned 309,273 shares of the company’s stock, valued at $4,264,874.67. The trade was a 6.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 39,149 shares of company stock valued at $539,865. 9.39% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On 10x Genomics

A number of institutional investors have recently made changes to their positions in TXG. EverSource Wealth Advisors LLC lifted its holdings in shares of 10x Genomics by 203.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 7,490 shares of the company’s stock worth $87,000 after acquiring an additional 5,025 shares during the last quarter. Focus Partners Wealth purchased a new stake in 10x Genomics in the first quarter valued at approximately $92,000. Sei Investments Co. purchased a new stake in 10x Genomics in the second quarter valued at approximately $151,000. HUB Investment Partners LLC acquired a new position in 10x Genomics during the second quarter worth $152,000. Finally, Orion Porfolio Solutions LLC purchased a new position in shares of 10x Genomics during the second quarter worth $158,000. 84.68% of the stock is currently owned by institutional investors and hedge funds.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.